Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control

Francesco Di Pierro,1 Nicola Villanova,2 Federica Agostini,2 Rebecca Marzocchi,2 Valentina Soverini,2 Giulio Marchesini21Scientific Department, Velleja Research, Milano, 2Diseases of Metabolism, S Orsola Malpighi Hospital, Bologna, ItalyBackground: Suboptimal glycemic control is a common situation i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/0f81c6f0d75840f58855d9da75664e32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f81c6f0d75840f58855d9da75664e32
record_format	dspace
spelling	oai:doaj.org-article:0f81c6f0d75840f58855d9da75664e322021-12-02T01:03:49ZPilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control1178-7007https://doaj.org/article/0f81c6f0d75840f58855d9da75664e322012-07-01T00:00:00Zhttp://www.dovepress.com/pilot-study-on-the-additive-effects-of-berberine-and-oral-type-2-diabe-a10428https://doaj.org/toc/1178-7007Francesco Di Pierro,1 Nicola Villanova,2 Federica Agostini,2 Rebecca Marzocchi,2 Valentina Soverini,2 Giulio Marchesini21Scientific Department, Velleja Research, Milano, 2Diseases of Metabolism, S Orsola Malpighi Hospital, Bologna, ItalyBackground: Suboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to reach glycemic targets. Basic research in diabetes is endeavoring to identify new actives working as insulin savers, use of which could delay the introduction of injectable insulin or reduce the insulin dose needed. Commonly available as a nutraceutical, berberine is a potential candidate.Methods and results: Because its low oral bioavailability can be overcome by P-glycoprotein inhibitors like herbal polyphenols, we have tested the nutraceutical combination of Berberis aristata extract and Silybum marianum extract (Berberol&reg;) in type 2 diabetes in terms of its additive effect when combined with a conventional oral regimen for patients with suboptimal glycemic control. After 90 days of treatment, the nutraceutical association had a positive effect on glycemic and lipid parameters, significantly reducing glycosylated hemoglobin, basal insulin, homeostatic model assessment of insulin resistance, total and low-density lipoprotein cholesterol, and triglycerides. A relevant effect was also observed in terms of liver function by measuring aspartate transaminase and alanine transaminase. The product had a good safety profile, with distinctive gastrointestinal side effects likely due to its acarbose-like action.Conclusion: Although further studies should be carried out to confirm our data, Berberol could be considered a good candidate as an adjunctive treatment option in diabetes, especially in patients with suboptimal glycemic control.Keywords: berberine, silymarin, glycosylated hemoglobin, diabetesDi Pierro FVillanova NAgostini FMarzocchi RSoverini VMarchesini GDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2012, Iss default, Pp 213-217 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Di Pierro F Villanova N Agostini F Marzocchi R Soverini V Marchesini G Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
description	Francesco Di Pierro,1 Nicola Villanova,2 Federica Agostini,2 Rebecca Marzocchi,2 Valentina Soverini,2 Giulio Marchesini21Scientific Department, Velleja Research, Milano, 2Diseases of Metabolism, S Orsola Malpighi Hospital, Bologna, ItalyBackground: Suboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to reach glycemic targets. Basic research in diabetes is endeavoring to identify new actives working as insulin savers, use of which could delay the introduction of injectable insulin or reduce the insulin dose needed. Commonly available as a nutraceutical, berberine is a potential candidate.Methods and results: Because its low oral bioavailability can be overcome by P-glycoprotein inhibitors like herbal polyphenols, we have tested the nutraceutical combination of Berberis aristata extract and Silybum marianum extract (Berberol&reg;) in type 2 diabetes in terms of its additive effect when combined with a conventional oral regimen for patients with suboptimal glycemic control. After 90 days of treatment, the nutraceutical association had a positive effect on glycemic and lipid parameters, significantly reducing glycosylated hemoglobin, basal insulin, homeostatic model assessment of insulin resistance, total and low-density lipoprotein cholesterol, and triglycerides. A relevant effect was also observed in terms of liver function by measuring aspartate transaminase and alanine transaminase. The product had a good safety profile, with distinctive gastrointestinal side effects likely due to its acarbose-like action.Conclusion: Although further studies should be carried out to confirm our data, Berberol could be considered a good candidate as an adjunctive treatment option in diabetes, especially in patients with suboptimal glycemic control.Keywords: berberine, silymarin, glycosylated hemoglobin, diabetes
format	article
author	Di Pierro F Villanova N Agostini F Marzocchi R Soverini V Marchesini G
author_facet	Di Pierro F Villanova N Agostini F Marzocchi R Soverini V Marchesini G
author_sort	Di Pierro F
title	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
title_short	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
title_full	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
title_fullStr	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
title_full_unstemmed	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
title_sort	pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/0f81c6f0d75840f58855d9da75664e32
work_keys_str_mv	AT dipierrof pilotstudyontheadditiveeffectsofberberineandoraltype2diabetesagentsforpatientswithsuboptimalglycemiccontrol AT villanovan pilotstudyontheadditiveeffectsofberberineandoraltype2diabetesagentsforpatientswithsuboptimalglycemiccontrol AT agostinif pilotstudyontheadditiveeffectsofberberineandoraltype2diabetesagentsforpatientswithsuboptimalglycemiccontrol AT marzocchir pilotstudyontheadditiveeffectsofberberineandoraltype2diabetesagentsforpatientswithsuboptimalglycemiccontrol AT soveriniv pilotstudyontheadditiveeffectsofberberineandoraltype2diabetesagentsforpatientswithsuboptimalglycemiccontrol AT marchesinig pilotstudyontheadditiveeffectsofberberineandoraltype2diabetesagentsforpatientswithsuboptimalglycemiccontrol
_version_	1718403299399434240

Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control

Ejemplares similares